AGMBAgomAb Therapeutics NV
$9.05
$9.05
$8.1852 weeks$17.57
Is the business good?
How good a business is AGMB?
AgomAb Therapeutics NV spent more than it took in: an operating loss of $59M on $1.6M of revenue, fiscal year to FY2025.
$59M
Operating loss · on $1.6M of revenue · fiscal year to FY2025
- Share count, year on year
- 0.00%
Share count, year on year · flat: no meaningful dilution
| Year | Operating margin |
|---|---|
| FY2023 | −12731% |
| FY2024 | −3943% |
| FY2025 | −3684% |
Details›
- Operating marginfiscal year to FY2025
- −3684%
- Net marginfiscal year to FY2025
- −3887%
- R&D as % of revenue
- 3038%
- Revenue, trailing twelve months
- $1.6M
- Net income, trailing twelve months
- −$63M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry